Aerovate Therapeutics (AVTE) Competitors $2.66 -0.01 (-0.37%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVTE vs. CTMX, IMUX, MGTA, GOSS, SAGE, KOD, PRQR, IMMP, CCCC, and ATAIShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include CytomX Therapeutics (CTMX), Immunic (IMUX), Magenta Therapeutics (MGTA), Gossamer Bio (GOSS), Sage Therapeutics (SAGE), Kodiak Sciences (KOD), ProQR Therapeutics (PRQR), Immutep (IMMP), C4 Therapeutics (CCCC), and Atai Life Sciences (ATAI). These companies are all part of the "medical" sector. Aerovate Therapeutics vs. CytomX Therapeutics Immunic Magenta Therapeutics Gossamer Bio Sage Therapeutics Kodiak Sciences ProQR Therapeutics Immutep C4 Therapeutics Atai Life Sciences CytomX Therapeutics (NASDAQ:CTMX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk. Do analysts rate CTMX or AVTE? CytomX Therapeutics presently has a consensus price target of $5.77, indicating a potential upside of 563.43%. Aerovate Therapeutics has a consensus price target of $2.25, indicating a potential downside of 15.41%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, CTMX or AVTE? CytomX Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$101.21M0.67-$570K$0.175.12Aerovate TherapeuticsN/AN/A-$75.52M-$2.99-0.89 Does the media favor CTMX or AVTE? In the previous week, Aerovate Therapeutics had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 7 mentions for Aerovate Therapeutics and 3 mentions for CytomX Therapeutics. Aerovate Therapeutics' average media sentiment score of 1.06 beat CytomX Therapeutics' score of 0.70 indicating that Aerovate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aerovate Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CTMX or AVTE more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Aerovate Therapeutics' net margin of 0.00%. CytomX Therapeutics' return on equity of -41.47% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics10.96% -41.47% 8.11% Aerovate Therapeutics N/A -90.19%-77.47% Does the MarketBeat Community prefer CTMX or AVTE? CytomX Therapeutics received 353 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 65.49% of users gave CytomX Therapeutics an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformCytomX TherapeuticsOutperform Votes37265.49% Underperform Votes19634.51% Aerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% Which has more risk and volatility, CTMX or AVTE? CytomX Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Do insiders and institutionals have more ownership in CTMX or AVTE? 67.8% of CytomX Therapeutics shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCytomX Therapeutics beats Aerovate Therapeutics on 14 of the 17 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.10M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.894.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book0.9510.216.946.30Net Income-$75.52M$153.61M$119.12M$225.93M7 Day Performance3.91%-2.00%-1.84%-1.32%1 Month Performance13.68%-7.47%-3.65%0.60%1 Year Performance-81.66%31.80%31.64%26.23% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate Therapeutics1.709 of 5 stars$2.66-0.4%$2.25-15.4%-81.7%$77.10MN/A-0.8951Positive NewsCTMXCytomX Therapeutics4.3795 of 5 stars$0.87-2.2%$5.77+563.4%-37.4%$69.86M$101.21M5.12170Short Interest ↓IMUXImmunic3.0786 of 5 stars$1.07+1.9%$12.25+1,044.9%-3.6%$94.58MN/A0.0070MGTAMagenta Therapeutics0.8555 of 5 stars$0.70-7.7%N/A+0.0%$42.44MN/A0.0067Gap DownGOSSGossamer Bio4.4297 of 5 stars$0.70-2.8%$9.20+1,220.9%-16.9%$161.98MN/A-2.18180SAGESage Therapeutics4.2697 of 5 stars$4.91flat$12.89+162.5%-75.1%$300.36M$86.46M-0.88690Analyst ForecastNews CoverageGap DownKODKodiak Sciences2.983 of 5 stars$5.79+2.7%$3.50-39.6%+138.3%$296.80MN/A0.0090PRQRProQR Therapeutics2.0614 of 5 stars$3.67+1.9%$7.13+94.1%+143.0%$294.05M$7.05M-11.47180IMMPImmutep1.3099 of 5 stars$1.96-3.0%$8.50+333.7%+4.8%$293.82M$5.14M0.002,021CCCCC4 Therapeutics2.652 of 5 stars$4.05-2.4%$10.00+146.9%+139.6%$292.94M$20.76M0.00150Analyst ForecastATAIAtai Life Sciences2.3795 of 5 stars$1.59-8.1%$9.00+466.0%+42.0%$290.30M$310,000.000.0083Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies CytomX Therapeutics Competitors Immunic Competitors Magenta Therapeutics Competitors Gossamer Bio Competitors Sage Therapeutics Competitors Kodiak Sciences Competitors ProQR Therapeutics Competitors Immutep Competitors C4 Therapeutics Competitors Atai Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
